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ABSTRACT 
Development of severe disease in Plasmodium falciparum malaria infection is 
thought to be, at least in part, due to sequestration of trophozoite-stage infected red 
blood cells in the microvasculature. The process of cytoadherence is mediated by 
binding of the parasite protein PfEMP-1 on the surface of infected red blood cells to 
endothelial cell receptors. Although antimalarial treatments rapidly kill parasites, 
significant mortality is still seen in severe malaria, particularly within 24 hours of 
hospital admission.  We find that cytoadherence of infected red blood cells continues 
for several hours after killing of the parasite by antimalarials; after 24 hours treatment 
using a range of antimalarials binding is approximately one third the level of 
untreated parasite cultures. This is consistent with maintained presence of PfEMP-1 
on the surface of drug-treated infected red blood cells.  A specific advantage of 
artesunate over other treatments tested is seen on addition of this drug to younger 
ring stage parasites, which do not mature to the cytoadherent trophozoite-stage.  
These findings show that cytoadherence, a potentially pathogenic property of P. 
falciparum infected red blood cells, continues long after the parasite has been killed. 
These data support the development of adjunctive therapies to reverse the 
pathophysiological consequences of cytoadherence. 
 
INTRODUCTION 
Plasmodium falciparum malaria is responsible for over a million deaths a year 1 with 
many of these fatalities occurring in infants in Africa.  An important aspect of the 
pathogenesis of severe malaria results from the ability of infected red blood cells to 
sequester in the microvasculature.  During the 48 h parasite growth stage inside a 
host red blood cell the parasite makes many changes to the cell. As well as 
becoming more metabolically active, and more rigid, the infected red blood cell 
becomes capable of adhering to the endothelial cells lining the blood vessels 2. Post-
 3 
mortem studies of severe malaria show high levels of infected red blood cells (iRBC) 
bound to microvasculature 3,4.  The involvement of sequestration in pathogenesis 
could be directly a result of blocking of the blood vessels, and/or downstream effects 
caused by the interaction between iRBC and the endothelium, including local 
inflammatory responses  5. 
 
Cytoadherence is mediated by a parasite protein PfEMP-1 which is a large protein 
comprising several external Duffy-binding-like (DBL) domains, encoded for by var 
genes. P. falciparum has around 60 var genes, of which only one is expressed at a 
time. This process of antigenic variation is a way in which the parasite evades 
recognition by host adaptive antibody immune responses and the large number of 
variants of PfEMP-1 also results in the potential to bind to many different host 
receptors 6.   
 
Of the fourteen cell adhesion receptors to which iRBC can bind, a few have been well 
characterized including ICAM-1, CD36 and Chondroitin Sulfate A (CSA).  ICAM-1 is 
of interest as it is linked to cerebral malaria 7.  Patients suffering with cerebral malaria 
have up-regulated levels of ICAM-1 in the brain and parasite isolates from patients 
suffering from cerebral malaria show higher binding to ICAM-1 protein 8,9.  CD36  is 
expressed on many types of endothelia (but negligibly in the brain) and has the ability 
to bind most patient isolates.  Adhesion to endothelium devoid of CD36 may be 
possible using platelets expressing CD36 as a bridging interaction 10. The 
carbohydrate CSA is uniquely implicated in placental adhesion during pregnancy. 
Parasites able to adhere to CSA express an unusually conserved PfEMP-1 which is 
expressed during malaria in pregnancy 11.  
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It is known that cytoadherence of iRBC induces signalling events in endothelial cells 
12,13.  Some of these signalling responses may help protect the host endothelium 
against damage, as suggested by the down-regulation of apoptotic genes in 
endothelial cells 14.  However, other effects may be damaging.  For example, the 
induction of ICAM-1 expression on endothelial cells occurs in response to iRBCs  14, 
which could lead to further sequestration of iRBC, as well as local leukocyte 
recruitment, amplifying pathology caused by adhesion or local inflammatory 
responses.  There is also evidence of induction of apoptosis and leakage in 
endothelial cells following adhesion of iRBC 15.  
 
Antimalarial treatments are effective at killing parasites where resistance has not 
developed; however, there is still a high mortality rate associated with severe malaria 
with most deaths occurring in the first 24 h after hospital admission 16.  It is clear that 
even after initiation of antimalarial treatment, patients continue to manifest worrying 
clinical signs 16.  One hypothesis, tested in this study, is that non-viable parasites 
killed by standard antimalarial treatment contribute to disease pathology by their 
continued ability to cytoadhere. To investigate this phenomenon, we have performed 
in vitro assays for cytoadherence with drug-treated P. falciparum iRBCs to ICAM-1 
and human endothelium under both static and flow conditions.   
 
Using a range of antimalarials we show that non-viable P. falciparum iRBCs retain 
the ability to cytoadhere at least 24 h after drug administration as a result of the slow 
rate of degradation of the surface protein PfEMP-1.   
 
MATERIALS AND METHODS 
 
Parasite Strains and Culture 
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Parasite lines ItG 17 and A4 18 were used in this study.  Both of these strains are of 
the IT lineage and are well characterized for their ability to bind to ICAM-1 and CD36 
19. ItG was selected on ICAM-1 protein and expression of the expected var gene 
confirmed by cloning and sequencing a DBLα tag from cDNA.  A4 was selected for 
binding to the monoclonal antibody BC6 20 followed by immunofluorescence analysis 
(IFA) of expressed PfEMP-1 and sequencing of the expressed var tag.  Populations 
used were >80% homogeneous for the expected var tag.  Parasites were cultured 
under standard conditions in RPMI 1640 medium (supplemented with 37.5 mM 
HEPES, 7 mM -glucose, 6 mM NaOH, 25 μg ml−1 gentamicin sulphate, 2 mM -
glutamine and 10% human serum) at a pH of 7.2, in a gas mixture of 96% nitrogen, 
3% carbon dioxide and 1% oxygen 21 and synchrony maintained using sorbitol lysis 
at ring stages 22.  Two cultures were maintained in parallel 24 h apart to allow stage-
matched controls for 24 hour time point experiments. 
 
Qualitative and quantitative measurement of PfEMP-1 levels of the surface of P. 
falciparum A4 iRBCs 
PfEMP-1 on the surface of live A4 iRBC was visualised by immunofluorescence 
using BC6 monoclonal primary antibody (1:50 dilution), a secondary rabbit anti-
mouse antibody (serotec) (1:100) followed by Alexa488 conjugated goat anti-rabbit 
antibody (molecular probes) (1:5000).  All washes and antibody dilutions were in 
Dulbecco’s PBS with 1% BSA and each incubation was at 37°C for 30 min.  Infected 
cells were stained with ethidium bromide (1 µg/ml), mounted on a microscope slide 
and analysed by confocal microscopy using Zeiss LSMPascal microscope and Zeiss 
Pascal and Photoshop software (Adobe).  For flow cytometry analysis staining was 
carried out as above then infected cells were diluted in PBS and 500,000 events (red 
blood cells) acquired on Beckman Coulter FACS XL, gated using forward scatter and 
side scatter to acquire red blood cell populations excluding debris and then FL-1 and 
FL-2 fluorescence intensity measured. Analysis was performed using WinMDi 
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software. Regions were drawn on density plots (i.e. Fig 4 b) of uninfected controls to 
gate uninfected cells such that <0.1% of the population fell into the region classed as 
ethidium bromide positive. This region was then used to create a histogram. Region 
R1 was created for A4var41 positive cells based on negative antibody controls, 
<0.1% of the ethidium bromide positive population fell into region R1 when no 
primary antibody was included. Similarly for the antigenically distinct strain ItG <0.1% 
of the ethidium bromide positive population fell into region R1 (not shown). The mean 
fluorescence intensity (MFI) of region R1 was used to quantitate the level of PfEMP-1 
on A4var41 positive infected red blood cells. The percentage of A4 iRBC that were 
classed as A4var41 positive remained at ~80%. 
 
Endothelial Cells 
Human umbilical vein endothelial cells (HUVEC) and human dermal microvascular 
endothelial cells (HDMEC) were purchased from Promocell and cultured as per 
manufacturer’s instructions. Cells at passage 4 to 6 were used for all experiments.  
Prior to experimentation cells were stimulated by the addition of 1 ng/ml TNF for 18 
hours.  This procedure allowed for the induction of ICAM-1 expression on the surface 
of the endothelial cells as verified by immunofluorescence microscopy and flow 
cytometry after immunofluorescence (data not shown). 
 
Adhesion assays 
All adhesion assays were carried out essentially as previously described 19. In brief: 
 
Flow Based Protein Assays 
Aminopropyltriethoxysilane (APES) treated microslides were coated with ICAM-1-Fc 
23 protein at 50 μg/ml in Dulbecco’s PBS.  Protein was allowed to adhere for 2 h, then 
slides were washed with 1% BSA/PBS and blocked in 1% BSA/PBS overnight at 
4°C.  Parasites were prepared to 3% parasitaemia and 1% haematocrit (hct) in 
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binding buffer (RPMI 1640 medium pH 7.2, supplemented with 6 mM glucose).   After 
flowing binding medium through the microslide for 2 min, prepared parasites were 
flowed through at a pump speed of 0.186 ml/min, to give a wall shear stress of 0.05 
Pa, for 5 minutes. This was followed by flowing binding buffer for 2 min.  All assays 
were carried out at 37°C.  Stationary adhered parasites were counted in 6 fields 
along the slide. Each experiment was performed in duplicate or triplicate and on 
three independent occasions. 
 
Static Endothelial Cell Assays 
Endothelial cells cultured as above were seeded onto 13 mm thermanox coverslips 
(Nunc) coated with 1% gelatin in 24 well plates.  Confluent cells were induced with 1 
ng/ml TNF for 18 hours and washed in culture medium before an assay.  Parasites 
were prepared to 1% hct and 3% parasitaemia in binding buffer. 0.5 ml of cell 
suspension were applied to each well and incubated at 37°C for 1 h with gentle 
resuspension by rotation every 10 min. Unbound cells were removed by 2 washes in 
binding buffer followed by 2 x 30 min gravity washes in binding buffer.  Cells were 
fixed with 1% glutaraldehyde for ≥1 h.  After staining with 5% Geimsa for 30 min, 
coverslips were washed in water, air dried and mounted using DPX hard set 
mounting medium.  6 – 10 areas of each cover slip were counted for the number of 
bound parasites.  Each experiment was performed in duplicate or triplicate and on 
three independent occasions. 
 
Flow Based Endothelial Cell Assays 
APES treated microslides were coated with 1% gelatin, 1% collagen for 45 minutes 
at 37°C. Endothelial cells at passage 3–5 were treated with trypsin to detach 
adherent cells (Promocell detach kit used as per manufacturers’ instructions).  Cell 
suspensions were applied to the microslides, and allowed to settle for 2 h at 37°C to 
form a confluent monolayer. After overnight growth with media exchange every hour, 
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TNF (1 ng/ml) was added to the confluent cells for 18 hours before the assay. 
Parasites were prepared at 3% parasitaemia and 1% hct in binding buffer. After 
flowing binding medium through the microslide for 2 min, prepared parasites were 
flowed through at a wall shear stress of 0.05 Pa for 5 min, followed by a wash with 
binding buffer (2 min).  Stationary adherent parasites were counted in at least 6 fields 
along the slide.  Each experiment was performed in duplicate or triplicate and on 
three independent occasions. 
 
Drug Treatment  
The effect of parasite viability on cytoadherence was tested using a range of drugs 
including artesunate, quinine, lumefantrine and piperaquine.  Final drug 
concentrations were chosen based on published peak plasma levels.  These were; 
500nM for artesunate, 24,25, 25µM for quinine 26,27, 15µM for lumefantrine 28,29, and 
100nM for piperaquine 26,30.  
The concentrations of drugs used were well above the IC50 determined for each 
(Table 1, supplementary information) and were confirmed to inhibit parasite 
development as assessed by Geimsa staining as described in the results section. 
Parasites were confirmed non-viable after treatment by continued culture for at least 
72 h post-treatment with no growth. The minimum exposure time to 500 nM 
artesunate to stop parasite growth was determined to be 30 minutes. Various 
exposure times greater than this followed by washing out of the drug did not affect 
binding phenotype 24 h following treatment (Supplementary Fig S1).  
Growth inhibition (IC50) assays were performed on ItG and A4 parasites using a 
standard fluoremetric assay 31,32.  
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Statistical Analysis 
Each binding experiment was performed in duplicate or triplicate and the mean 
calculated. Results shown are the mean of three independent experiments +/- SD. 
Statistical significance was calculated using a two tailed t-test.   
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RESULTS 
Cytoadherence of artesunate treated P. falciparum ItG iRBCs to ICAM-1 under 
flow 
Adhesion of P. falciparum ItG iRBC to ICAM-1 protein under flow was assayed 
following 4, 8 and 24 h artesunate (500 nM) treatment of trophozoite (24 h post 
invasion) stage parasites.  Parasite development as assessed by geimsa staining 
appeared to halt after 4 h treatment (Fig 1a) and parasites were noticeably pyknotic 
following 8 h treatment. As described in the Methods section, parasites were not 
viable for culture following drug treatment. 
 
No significant difference in binding was observed for parasites exposed to artesunate 
for 4 h compared to untreated parasites (Fig. 1b).  Following 8 h exposure, a slight 
reduction in binding was seen and following 24 h artesunate treatment adhesion to 
ICAM-1 was reduced to ~30% of control levels (P <0.01, Fig 1).  The concentration of 
artesunate used (500 nM) was chosen as it falls in the normal range reported for 
observed plasma concentrations (see Methods and Supplementary Table 1), 
however, similar binding phenotypes were observed for artesunate concentrations 
ranging from 20 nM to 12.5 µM (Supplementary Fig S2).  
 
Cytoadherence of artesunate treated P. falciparum ItG iRBCs to human 
endothelial cells 
Adhesion of P. falciparum ItG iRBCs to human endothelial cells (HUVEC and 
HDMEC) was assessed under both static and flow conditions following 4, 8 and 24 h 
artesunate (500 nM) treatment of trophozoite (24 h post invasion) stage parasites. 
 
As described in the Methods section, binding assays were performed with confluent 
monolayers of TNF (1 ng/ml, 18 h) activated endothelial cells.  Under these 
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conditions HUVEC express the receptor ICAM-1, whereas HDMEC express both 
CD36 and ICAM-1. 
 
Under static conditions, there was no significant difference in the level of binding to  
either HUVEC or HDMEC of P. falciparum ItG iRBCs incubated for 4 h with 
artesunate (500 nM) compared to the untreated controls to (Fig. 2 a,b).  Following 8 h 
exposure, a slight reduction in binding was seen and following 24 h artesunate 
treatment adhesion to both HUVEC (P<0.01) and HDMEC (P<0.05) was reduced to 
~30% of control levels (Fig 2a,b). 
 
Essentially the same binding phenotypes were observed for adhesion measured 
under flow, with up to 8 h exposure to artesunate (500 nM) not significantly affecting 
adhesion to both HUVEC or HDMEC, whilst 24 h exposure to artesunate (500 nM) 
did reduce the levels of binding to both cell types to 25-30% of control levels (Fig. 
2c,d). 
 
Cytoadherence of other P. falciparum isolates to other receptors after 
artesunate treatment 
Similar results to those seen for ItG adhesion after artesunate treatment were also 
seen with two other parasite isolates. A4, like ItG, binds to both ICAM-1 and CD36 
but generally at lower levels than ItG 19. The adhesion of A4 to ICAM-1 protein under 
flow and to HDMEC under static conditions was assessed. No significant reduction in 
adhesion was seen after 8 h treatment of trophozoite-stage parasites with artesunate 
(500 nM), however, after 24 hours treatment adhesion was reduced to 25-30% of 
controls. Additionally the CSA binding strain CS2 33 was assayed for cytoadherence 
to CSA protein under flow conditions. No reduction in adhesion was seen after 8 h 
treatment and significant adhesion at around 25% control levels was observed after 
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24 h treatment. Experiments after 4 and 24 h drug treatment showed that ItG binding 
to CD36 was similarly affected (Supplementary Fig S3) 
 
Measurement of PfEMP-1 levels on the surface of drug treated P. falciparum 
iRBCs 
To determine whether the continued ability of non-viable parasites to adhere is due to 
the persistence of the PfEMP-1 complex on the infected erythrocyte membrane, 
single cell and population immunofluorescence measurements were performed using 
the monoclonal antibody mAb BC6, specific for the PfEMP-1 A4var41 variant 18.   
 
Confocal laser scanning microscopy of P. falciparum A4 iRBCs after 
immunofluorescent labelling with the primary monoclonal antibody BC6 revealed the 
characteristic punctate distribution of PfEMP-1 on the outer erythrocytic membrane 
(Fig. 3a.).  Qualitatively, the distribution of PfEMP-1 was not observably different in P. 
falciparum iRBCs treated for up to 24 h with 500 nM artesunate (Fig. 3a).  Analysis 
by flow cytometry confirmed that ~80% of iRBCs expressed detectable levels of 
A4var41 PfEMP-1 (Fig. 3b). This population percentage did not change through the 
course of these experiments. Following treatment with artesunate (500 nM, 24 h), the 
mean fluorescence of PfEMP-1 surface positive iRBCs was reduced to approximately 
65% the level of untreated cells (P < 0.01, n=3, Fig. 3c, d).   Notably, PfEMP-1 could 
still be detected on iRBC surface after 4 days treatment (data not shown). 
 
Cytoadherence of P. falciparum ItG iRBCs to ICAM-1: Comparison of 
antimalarials   
Adhesion of P. falciparum ItG iRBC to ICAM-1 protein under flow was assayed 
following 4, 8 and 24 h drug treatment of trophozoite (24 h post invasion) stage 
parasites.  The antimalarial drugs tested were artesunate (500 nM), quinine (25 µM), 
lumefantrine (15 µM) and piperaquine (100 nM).  As described in the Methods 
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section, all drugs were used at concentrations comparable to published peak plasma 
concentrations and were confirmed to result in the abrogation of parasite viability.   
 
The binding phenotypes for all treatments were observed to be very similar, with no 
significant difference in binding observable after 4 h drug exposure (Fig. 4a).  As 
observed previously, a small reduction in binding was observed for parasites 
exposed to 8 h artesunate (Fig. 4b) but no significant difference relative to control 
cells was observed for all other drugs (Fig. 4b).  A significant reduction in iRBC 
binding was observed following 24 h exposure to all of the drugs, with binding ~30% 
of control levels (Fig. 4c). 
 
Cytoadherence of P. falciparum ItG iRBCs to ICAM-1: Comparison of 
antimalarials administered to ring-stage parasites 
As the antimalarial drugs used in this study have different pharmacodynamic 
properties, especially in regards to cell cycle specificity, binding experiments to 
ICAM-1 under flow conditions were repeated as described above but drug exposure 
was performed on ring-stage (12 h post invasion) parasite cultures. These younger 
ring stage parasites represent the pre-cytoadherent circulating population.  
 
Adhesion to ICAM-1 protein under flow, was determined after 24 h exposure of ring-
stage P. falciparum ItG iRBCs to artesunate (500 nM), quinine (25 µM), lumefantrine 
(15 µM) and piperaquine (100 nM) relative to untreated control cells.  Significant 
differences were observed between the various treatments.  Artesunate treated 
parasites were unable to mature to trophozoites and non-viable ring parasites were 
observed after 24 h exposure (Fig. 5a), whilst quinine and lumefantrine treated 
parasites matured to late trophozoites before dying and appearing pyknotic (Fig. 5a).  
Piperaquine treated parasites appeared to show an intermediate amount of 
development to late ring/early trophozoite before becoming non-viable.  Binding 
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experiments revealed that control parasites allowed to develop for 24 h from ring 
stage parasites to trophozoites displayed characteristic levels of adhesion whilst 
control ring-stage parasites, as expected, displayed a very low level of 
cytoadherence (Fig. 5b).  Artesunate treated parasites, which as described had failed 
to mature showed little cytoadherence, whilst quinine and lumefantrine treated 
parasites displayed high levels of adhesion comparable to control trophozoite-stage 
iRBC (Fig. 5b).  Treatment of parasites with piperaquine resulted in intermediate 
levels of binding, ~50% of control levels (Fig. 5b).  
 
 
 15 
DISCUSSION 
In this study we have assessed the ability of non-viable parasites killed by 
antimalarial treatments to cytoadhere, a process important in the pathophysiology of 
disease.  
 
Our data demonstrate that P. falciparum iRBC are capable of cytoadherence for at 
least 24 h after lethal dosages of a range of antimalarial drugs.  The antimalarial 
drugs tested in this study were artesunate, quinine, lumefantrine and piperaquine at 
clinically relevant concentrations, chosen to mimic peak plasma drug levels.  The 
cytoadherence phenotype of iRBCs was measured using both static and flow assays 
and using a range of parasite strains (ItG, A4 and CS2) against purified receptor 
proteins (ICAM-1, CD36 and CSA) and endothelial cells (HUVEC and HDMEC). 
 
Consistent with the continued ability to cytoadhere, we observed the characteristic 
punctate distribution of PfEMP-1 on the surface of P. falciparum iRBC at significant 
levels (~65% of control) following 24 h antimalarial treatment (Fig. 3).   
 
These data illustrate the stability of the changes made to the red blood cell by the 
parasite such that the remodelling of the infected red blood cells is maintained after 
the parasite is rendered non-viable.  Nevertheless, quantification of the PfEMP-1 
levels on iRBCs surface showed some reduction after drug treatment, consistent with 
a degree of degradation/loss of the protein. This reduction in PfEMP-1, combined 
with potential reduction in other cytoadherence-related parasite proteins, i.e. KAHRP, 
could explain the reduced levels of cytoadherence seen after 24 h treatment. This 
could be comparable to that seen when mutations are present in haemoglobin, i.e. 
haemoglobin C (HbC), and sickle haemoglobin (HbS). In these cases infected 
erythrocytes show a slightly reduced and abnormal display of PfEMP-1 and 
concurrently reduced cytoadherence 34. 
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Testing a selection of antimalarial drugs showed that the effect on mature (24 h post 
infection) trophozoite cytoadherence was not drug specific; the same level of 
adhesion was seen after 24 h treatment with all of the antimalarials tested (Fig. 3). 
 
Previously published data has implied that antimalarial drugs including quinine, 
halofantrine, artesunate and artemether reduce cytoadherence and/or rosetting in P. 
falciparum 35.  In the Udomsangpetch et al., study, parasites (presumably ring stage 
circulating parasites) were exposed to antimalarial drugs for 2 to 24 h, washed and 
grown in culture until control parasites (no drug exposure) were at late 
trophozoite/early schizont stage.  Depending on the drug treatment these authors 
reported a range of binding phenotypes, most notably parasites exposed to 
artesunate and artemether were reported to result in ≥50 % inhibition of both 
cytoadherence (static assay) and rosetting.  It was concluded by these authors that 
the observed differences between the various drugs on parasite adhesion probably 
reflected differences in the susceptibility of asexual stage parasites to antimalarials. 
 
We show a similar effect when drug treatment is added to ring stage (young) 
parasites. As shown in Fig. 5a, the various antimalarials used inhibited parasite 
growth at different stages of the asexual cycle.  This is consistent with previous 
pharmacodynamic data on the mode of action of these drugs.  The minimum 
exposure time to artesunate (500 nM) to render parasites non viable was just 30 
minutes, reflecting the fast mode of action of this drug upon activation of the 
endoperoxide bridge 36,37. Furthermore the drug is known to be active against young 
ring stage parasites. The activity of lumefantrine, quinine and piperaquine, however, 
is based on the disruption of heme detoxification 38,39 occurring later in development 
during haemoglobin digestion by trophozoite stage parasites 36,40,41.   The 
pharmacodynamic differences of these drugs when administered to ring stage 
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parasites results in mismatched comparisons of binding phenotypes. Essentially the 
assays measured the adhesion of dead ring stage parasites for the artesunate 
treated group, against the adhesion of dead trophozoite stage parasites for the 
quinine, lumefantrine and piperaquine treated groups (Fig. 5a,b).  The significant 
reduction in adhesion seen by artesunate treated parasites in Fig. 5 and in the 
Udomsangpetch et al., study 35 simply reflect that these groups consist of ring stage 
parasites that have insufficient levels of binding proteins, i.e.  PfEMP-1, exported to 
the erythrocyte membrane surface at that stage.   
 
The significant observation of our study is that dead parasites retain the ability to 
cytoadhere irrespective of the antimalarial treatment administered.  However, we can 
hypothesise that administration of fast, ring stage acting antimalarials such as 
artesunate will result in a reduction of de novo cytoadherence when administered in 
vivo due to the their ability to prevent maturation of parasites to mature cytoadherent 
stages.   The persistence of cytoadherence for many hours after treatment, despite 
rapid effects on parasite viability fits with, and may in part explain, the clinical 
observation of a high (84 % in one study) mortality rate in first 24 hours after hospital 
admission after initiation of antimalarial treatment 16.   Even though treatment is killing 
the parasites rapidly, we show that they would still be able to cytoadhere 24 h 
following treatment, potentially still contributing to disease pathology.   
 
It is conceivable that the observed phenomenon of continued adherence by non-
viable P. falciparum iRBCs may be targeted by adjuvant therapies designed to 
prevent or preferably reverse cytoadherence.  Indeed, studies have recently been 
performed with Levamisole, which was shown to reduce sequestration of P. 
falciparum in patients by inhibition of CD36 dephosphorylation 42.    
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In summary, this study has assessed the cytoadherence capability of drug-killed P. 
falciparum iRBCs. Our data demonstrate that non-viable parasites, irrespective of 
treatment retain the ability to cytoadhere for up to 24 h.  This phenomenon is due to 
the stability of the changes made to the host red blood cell by the parasite, as 
illustrated by the continued presence of PfEMP-1 on the surface of iRBC after loss of 
parasite viability.  This continued capacity for cytoadherence could contribute to 
disease pathology following treatment. It is hypothesised that fast and ring stage 
acting antimalarials such as the endoperoxides may be therapeutically more 
favourable by their ability to prevent de novo adhesion, but adjunctive therapy 
strategies that can also reverse cytoadherence may also be advantageous in 
addressing the high mortality seen in severe malaria early after hospital admission  
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FIGURE LEGENDS 
 
Figure 1 
Phenotype of trophozoite-stage ItG iRBC after artesunate treatment. A) Geimsa 
stained smears of ItG infected red blood cells after 0, 4, 8, 24 hours treatment with 
500 nM artesunate under culture conditions.  B) Adhesion to ICAM-1 protein (50 
µg/ml) under flow conditions (0.05 Pa shear stress) after 0, 4, 8 or 24 hours 
treatment with 500nM artesunate. Mean of three independent experiments ± 
standard deviation (SD). * P <0.05 ** P<0.01 compared to untreated control (c) 
trophozoites. 
 
 
Figure 2 
Adhesion of trophozoite-stage ItG iRBC to endothelial cells after 0, 4, 8 or 24 hours 
artesunate treatment. Binding under static conditions to A) HUVEC and B) HDMEC 
after TNF stimulation (1 ng/ml 18 hours) showing bound iRBC per mm2 confluent 
endothelial cells.  Binding under flow conditions to C) HUVEC and D) HDMEC after 
TNF stimulation of endothelial cells showing percent of control (untreated 
trophozoites) binding. Each represents mean of three independent experiments ± 
SD.  * P <0.05 ** P<0.01 compared to untreated controls (c). 
 
 
Figure 3 
Adhesion of trophozoite-stage ItG iRBC to ICAM-1 protein under flow conditions after 
4, 8 and 24 hours treatment with artesunate (art) (500 nM), quinine (quin) (25 µM), 
lumefantrine (lum) (15 µM) or piperaquine (pip) (100 nM). Results are mean of three 
independent experiments ± SD. 
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Figure 4 
Analysis of PfEMP-1 on the surface of live trophozoite-stage A4 iRBC. after 
immunofluorescence using the primary antibody BC6. A) Confocal fluorescence 
images of (i) top plane, and (ii) centre plane of BC6 fluorescence, (iii) ethidium 
bromide labelling of parasite, and phase contrast images (iv), after 0 (upper) 4 
(middle) or 24 hours (lower) artesunate treatment. Scale bar (2 µM) on phase 
contrast image. B) Quantitation of PfEMP-1 levels by flow cytometry analysis after 
BC6 primary antibody and Alexa488 coupled secondary antibody (FL-1, X axis) and 
counterstaining infected red blood cells with ethidium bromide (FL-2, Y axis).  In the 
density plots uninfected red blood cells are the population in the lower left. Box R1 
represents BC6 positive infected red blood cells. Plot i) shows 0 h culture, plot ii) 
shows the culture after 24 hours artesunate treatment. C) Histogram showing 
quantitation of BC6 positive fluorescence intensity (X axis) of the infected population 
(gated as ethidium bromide positive) untreated trophozoites (open black) or after 
artesunate (500 nM) 24 h (solid red). D) Mean fluorescence intensity (MFI) for 
PfEMP-1 positive population (gate R1) mean ± SD for three independent 
experiments. 
 
Figure 5 
A) Geimsa stained smears of ItG iRBC 24 hours after addition of indicated drug 
treatment to ring stage (young) parasites. B) Adhesion to ICAM-1 protein under flow 
conditions 24 hours after addition of treatment to ring stage (young) parasites.   
 
Figure S1 
Trophozoite-stage ItG iRBC adhesion to ICAM-1 protein under flow conditions after 
artesunate treatment for 30 min to 24 hour treatment, followed by wash out of 
artesunate and adhesion assay 24 hours after initial drug addition (the 0 h time 
point). After 30 min (or longer) exposure parasites were non-viable and development 
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stopped as assessed by Geimsa staining. After 0 and 15 min artesunate treatment 
before wash out parasites had matured as untreated controls and hence were at 
(non-cytoadherent) ring stage 24 hours following treatment, so were not assayed. 
Mean of two experiments ± SD. 
 
Figure S2 
Trophozoite-stage ItG iRBC adhesion to ICAM-1 protein under flow conditions after 6 
or 24 h treatment with various concentrations of artesunate from 20 nM to 12.5 µM. 
Mean of two experiments +SD  
 
Figure S3 
Adhesion of other parasite isolates and to other adhesion receptors. Adhesion of 
trophozoite-stage A4 iRBC after 0, 4, 8, or 24 h artesunate (500 nM) treatment to 
ICAM-1 protein under flow conditions (A) or to HDMEC under static conditions (B). 
Adhesion of trophozoite-stage CS2 iRBC to CSA under flow conditions after 0, 4, 8 or 
24 h artesunate (500 nM) treatment (C). and Adhesion of trophozoite-stage ItG iRBC 
to CD36 protein under static conditions after 4 h or 24 h artesunate (500 nM) 
treatment (D). 
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